MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
70.65
-0.13 (-0.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.78
Open70.85
Bid0.00 x 4000
Ask0.00 x 900
Day's Range70.52 - 71.38
52 Week Range52.83 - 71.58
Volume6,460,371
Avg. Volume8,129,498
Market Cap187.896B
Beta1.06
PE Ratio (TTM)145.67
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.92 (2.70%)
Ex-Dividend Date2018-09-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Exploring Idexx Laboratories’ Operational Performance
    Market Realist8 hours ago

    Exploring Idexx Laboratories’ Operational Performance

    Idexx Laboratories (IDXX) incurred general and administrative expenses of $61.08 million in the second quarter, compared with $55.46 million in the second quarter of 2017. Its sales and marketing expenses increased from $87.69 million in the second quarter of 2017 to $96.25 million in the second quarter due to increased personnel-related costs. Its research and development expenses increased from $26.9 million in the second quarter of 2017 to $29.51 million in the second quarter.

  • How Idexx Laboratories Is Positioned in 2018
    Market Realist8 hours ago

    How Idexx Laboratories Is Positioned in 2018

    Idexx Laboratories’ (IDXX) products and services cater to the companion animal, veterinary, livestock, poultry, dairy, and water testing markets. The company also sells portable electrolytes and blood gas analyzers. So far in 2018, Idexx Laboratories stock has generated more than 50.0% returns for investors.

  • Allergan’s First Medical Aesthetics Innovation Center in China
    Market Realist16 hours ago

    Allergan’s First Medical Aesthetics Innovation Center in China

    Allergan (AGN) announced on September 19 that it plans to build its first Medical Aesthetics Innovation Center in the High-Tech Zone in Chengdu, China. The Medical Aesthetics and Innovation Center is expected to have a sophisticated training center for the healthcare professionals in the medical aesthetics field. For its medical aesthetics customers, the Center plans to feature an education and product experience space.

  • J&J Files for US Approval of Cancer Drug Erdafitinib
    Market Realist17 hours ago

    J&J Files for US Approval of Cancer Drug Erdafitinib

    On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.

  • Allergan’s Stock Price Performance in September
    Market Realist19 hours ago

    Allergan’s Stock Price Performance in September

    Allergan (AGN) is a specialty pharmaceutical company that develops a variety of products through internal programs as well as in collaboration with other companies. Allergan’s stock price has decreased nearly 0.6% to its closing price of $191.31 on September 21 compared to its closing price on September 20.

  • A Look at Johnson & Johnson’s Valuation This Month
    Market Realistyesterday

    A Look at Johnson & Johnson’s Valuation This Month

    On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.

  • OpGen signs deal with New York health department to research superbugs
    American City Business Journalsyesterday

    OpGen signs deal with New York health department to research superbugs

    The Maryland biotech hopes its new superbug contract with Merck and the state of New York puts it on the national map for drug-resistant disease research.

  • Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market
    Bloomberg2 days ago

    Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market

    Roche Holding AG is starting to look more like a niche player in the hottest new field in oncology, as lung-cancer study results unveiled on Monday failed to meet the benchmark set by U.S. rival Merck & Co. It’s still unclear whether and how much Roche’s drug Tecentriq can extend the lives of patients with the most common type of lung cancer when added to chemotherapy, the Basel, Switzerland-based company said in a patient trial presented Monday at the World Conference on Lung Cancer in Toronto. The results mean Roche will need to concentrate for now on less common -- and less lucrative -- types of tumors.

  • American City Business Journals2 days ago

    Merck subsidiary plans $48M investment, 115 jobs in Albany area over five years

    ILÚM will partner with health care company OpGen Inc., the New York Department of Health and the Wadsworth Center on a new "research program to detect, track and manage antimicrobial-resistant infections at healthcare institutions statewide."

  • With An ROE Of 4.2%, Has Merck & Co Inc’s (NYSE:MRK) Management Done Well?
    Simply Wall St.2 days ago

    With An ROE Of 4.2%, Has Merck & Co Inc’s (NYSE:MRK) Management Done Well?

    This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...

  • Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
    Zacks5 days ago

    Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

    Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

  • New Indications Are Expected to Drive Future Growth of Keytruda
    Market Realist5 days ago

    New Indications Are Expected to Drive Future Growth of Keytruda

    According to Goldman Sachs analyst Jami Rubin, Merck’s (MRK) Keytruda can earn annual revenues as high as $16.0 billion by 2025. Credit Suisse expects the drug to report peak sales of about $10.0 billion by 2023. According to Trefis estimates, Keytruda is expected to attain peak sales of ~$8.0 billion going forward.

  • Keytruda Is a Major Growth Asset for Merck in 2018
    Market Realist5 days ago

    Keytruda Is a Major Growth Asset for Merck in 2018

    In the first half of the year, Keytruda accounted for 15.27% of Merck’s (MRK) total revenues. Keytruda earned more than 40.0% of its total sales from international markets, despite the company having launched the drug only as a monotherapy and not as a combination regimen in these markets. By the end of the first half of the year, Keytruda was earning 60.0%–65.0% of its revenues from sales to lung cancer patients.

  • Why Merck Stock Has Risen 28.2% Year-to-Date
    Market Realist5 days ago

    Why Merck Stock Has Risen 28.2% Year-to-Date

    Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.

  • Motley Fool5 days ago

    How Do Drugs Compete Against Each Other?

    Investors can keep an eye on these four factors to tell which drugs will out-compete the rest.

  • Flexible labs, co-working space: Big Pharma is rethinking real estate
    American City Business Journals5 days ago

    Flexible labs, co-working space: Big Pharma is rethinking real estate

    At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks6 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist6 days ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • MarketWatch6 days ago

    Galectin stock lifts 15% premarket on early cancer combination trial results

    Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .

  • How Accenture’s Partnership with Merck Could Be Helpful
    Market Realist6 days ago

    How Accenture’s Partnership with Merck Could Be Helpful

    Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.

  • GuruFocus.com6 days ago

    Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...

    Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.

  • Can Accenture Meet Its Operating Margin Guidance in Q4 2018?
    Market Realist7 days ago

    Can Accenture Meet Its Operating Margin Guidance in Q4 2018?

    Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist7 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Accenture, Merck & Amazon AWS Partner for Cloud Platform
    Zacks7 days ago

    Accenture, Merck & Amazon AWS Partner for Cloud Platform

    Accenture's (ACN) latest partnership is likely to boost its Products segment.

  • MarketWatch7 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.